Estimated annual budget savings attributable to the introduction of biosimilar infliximab for the treatment of adult rheumatoid arthritis patients, according to three different scenarios
| Scenarios | Annual savings in Alsace (€) | Annual savings in France (€) |
|---|---|---|
| Baseline scenario | 0 | 0 |
| Biosimilar scenario 1 | 385 642 | 13 581 854 |
| Biosimilar scenario 2a | 38 918 | 1 370 646 |
| Biosimilar scenario 2b | 112 874 | 3 975 288 |
| Biosimilar scenario 3a | 115 693 | 4 074 570 |
| Biosimilar scenario 3b | 192 821 | 6 790 926 |
| Biosimilar scenario 3c | 308 514 | 10 865 497 |